Ketema Daniel Bekele, Alene Muluneh, Assemie Moges Agazhe, Yismaw Leltework, Merid Mehari Woldemariam
Department of Public Health, College of Health Science, Debre Markos University, Debre Markos, Ethiopia.
Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences and Specialized Comprehensive Hospital, University of Gondar, Gondar, Ethiopia.
Arch Public Health. 2020 Jul 31;78:69. doi: 10.1186/s13690-020-00448-5. eCollection 2020.
The emergency of drug resistant tuberculosis is a major public health concern worldwide including Ethiopia. However, little is known about risk factors of mortality among drug resistant tuberculosis patients in the study site. Thus, this study was aimed to estimate the risks factors for mortality among drug resistant tuberculosis patients registered for drug-resistant treatment in Amhara region, Ethiopia.
An institutional-based retrospective cohort study was carried out among laboratory-confirmed drug-resistant tuberculosis patients ( = 498) who were initiated treatment for drug-resistant tuberculosis between September 1, 2010, and December 31, 2017. The demographic and clinical characteristics of the patients were obtained from the register of patients treated for drug-resistant tuberculosis. The data were entered using EpiData version 4.2 and exported to Stata Version 14.1 for further analysis. Descriptive measures were used to characterize the study participants. Kaplan-Meier was used to estimate the survival time of the patients. Cox proportional hazard model was used to identify risk factors for mortality. Hazard Ratio (HR) with 95% confidence interval was used to report the strength of association between risk factors and mortality.
Death was observed among 14.2% ( = 70) of the 498 patients who met the inclusion criteria. The incidence rate of death was 8.20 (95% CI: 7.62, 20.50) per 1000 Person-months in the course of follow-up. The median age was 29.30 years (IQR:23-41). Age 45 years and above (adjusted hazard ratio (AHR) = 1.28: 95% CI: 1.10, 1.68), smoking cigarette (AHR = 1.39: 95% CI:1.27,3.18), tuberculosis related complication (AHR = 9.31:95% CI:5.11,16.97), anemia (AHR = 3.04:95% CI:1.14, 9.20), HIV/AIDS (AHR = 1.34:95% CI:1.25, 3.35), previous tuberculosis treatment history (AHR = 1.37:95% CI:1.16, 1.86), and diabetes mellitus (AHR = 1.85:95% CI:1.24,5.71) were identified risk factors for mortality.
This study concluded that drug-resistant tuberculosis mortality remains high in the study site. Age 45 years and above, smoking cigarette, tuberculosis related clinical complication, being anemic at baseline, HIV/AID, previous tuberculosis treatment history, and diabetes mellitus were identified risk factors for mortality. Continual support of the integration of TB/HIV service with emphasis and working on identified risk factors may help in reducing drug-resistant tuberculosis mortality.
耐药结核病的出现是包括埃塞俄比亚在内的全球主要公共卫生问题。然而,关于研究地点耐药结核病患者的死亡风险因素知之甚少。因此,本研究旨在评估在埃塞俄比亚阿姆哈拉地区登记接受耐药治疗的耐药结核病患者的死亡风险因素。
对2010年9月1日至2017年12月31日期间开始接受耐药结核病治疗的实验室确诊耐药结核病患者(n = 498)进行了一项基于机构的回顾性队列研究。患者的人口统计学和临床特征来自耐药结核病治疗患者登记册。数据使用EpiData 4.2版本录入,并导出到Stata 14.1版本进行进一步分析。描述性指标用于描述研究参与者的特征。Kaplan-Meier法用于估计患者的生存时间。Cox比例风险模型用于识别死亡风险因素。风险比(HR)及其95%置信区间用于报告风险因素与死亡之间关联的强度。
在符合纳入标准的498名患者中,有14.2%(n = 70)死亡。随访期间,每1000人月的死亡发病率为8.20(95%CI:7.62,20.50)。中位年龄为29.30岁(IQR:23 - 41)。45岁及以上(调整后风险比(AHR)= 1.28:95%CI:1.10,1.68)、吸烟(AHR = 1.39:95%CI:1.27,3.18)、结核病相关并发症(AHR = 9.31:95%CI:5.11,16.97)、贫血(AHR = 3.04:95%CI:1.14,9.20)、艾滋病毒/艾滋病(AHR = 1.34:95%CI:1.25,3.35)、既往结核病治疗史(AHR = 1.37:95%CI:1.16,1.86)和糖尿病(AHR = 1.85:95%CI:1.24,5.71)被确定为死亡风险因素。
本研究得出结论,研究地点的耐药结核病死亡率仍然很高。45岁及以上、吸烟、结核病相关临床并发症、基线时贫血、艾滋病毒/艾滋病、既往结核病治疗史和糖尿病被确定为死亡风险因素。持续支持结核病/艾滋病毒服务整合,并重点关注已确定的风险因素,可能有助于降低耐药结核病死亡率。